MicroPort CardioFlow Medtech Corporation(微創心通醫療科技有限公司)(the “Company”) is a medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases, which has several subsidiaries including Shanghai MicroPort CardioFlow Medtech Company Limited (collectively "MicroPort CardioFlow" or "the Group").
Our self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product VitaFlow®; was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. Our second generation product VitaFlow Liberty™ was approved by the NMPA in August 2021 in China. Currently VitaFlow Liberty™ is also under clinical trial in Europe,we have applied for CE Mark of VitaFlow Liberty™ on December 2021.